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cancer epidemioloGY
Current and future cancer burden in Saudi Arabia: 
meeting the challenge
Using the SEER Joinpoint regression program, Ibrahim and coll
leagues projected secular trends in cancer incidence based on 
statistics for Saudi Arabia from 2000 to 2004. They estimate 
that by the year 2020 and 2030 there will be a 6lfold and 10l
fold increase, respectively, in cancer in males compared with the 
burden in 2004. For females, the corresponding increase will be 
5lfold and 8lfold. The authors note that current agelstandardl
ized incidence rates for Saudi Arabia are among the lowest in the 
world, but that future rates could increase considerably and place 
enormous demands on healthcare resources. The same could be 
true of other developing countries, who may also need to examine 
future cancer burden.
diaGnosis and risK stratification
S-phase fraction as a useful marker for prognosis 
and therapeutic response in patients with aplastic 
anemia
Tripathi and colleagues investigated the Slphase fraction (SPF) 
(a measure of proliferative activity) to explore its relationship 
with disease characteristics, response to therapy, and as a means 
of discriminating among aplastic anemia patients with different 
prognoses. SPF was analyzed by flow cytometry at the time of dil
agnosis in 53 consecutive patients and in 30 agel and sexlmatched 
controls. Patients with SPF greater than the median of 0.59% had 
advanced age and an elevated serum lactate dehydrogenase level. 
During a median followlup of 18 months, 3.7% of patients with 
SPF ≤0.59% and 11.5% with SPF >0.59% developed dysplasia 
and one patient with SPF >0.59 converted into AML. A signifil
cantly higher overall response rate (53.9%) developed in patients 
with SPF >0.59% than in patients with SPF ≤0.59% (22.2%) 
at 6 months. The authors conclude that SPF at diagnosis may 
provide information on expected response to immunosuppressive 
therapy and propensity to evolve into MDS/AML and thus conl
tribute to therapeutic decision making.
cancer chemotherapY  
Gemcitabine/5-fluorouracil/leucovorin for the 
treatment of advanced pancreatic carcinoma
Since the response rate and median survival with gemcitabine 
monotherapy is relatively poor, Malayeri and colleagues evalul
ated this combination protocol in 37 patients with advanced or 
metastatic pancreatic cancer who were chemotherapy and radiol
therapy naïve. The median overall survival time was 6.5 months 
(range, 1.0 to 15.5 months). No grade III/IV toxicities were seen. 
Despite the poor survival data, the investigators concluded that 
the combination is active and well tolerated and merits further 
evaluation in prospective, randomized studies since it may be a 
valuable alternative to gemcitabine monotherapy.
rare hematoloGic maliGnancies
Biological features and outcome of biphenotypic 
acute leukemia: a case series
Mikulic and colleagues identified 21 cases of biphenotypic acute 
leukemia (BAL) in a review of 535 newly cases of acute leukemia 
diagnosed over an 11lyear period. The complete remission rate 
with highldose chemotherapy was 72% and the overall survival 
at 5 years was 21%. Patients that received AMLloriented chel
motherapy had a higher complete remission rate than those who 
received ALLloriented chemotherapy. Despite progress in the 
treatment of acute leukemia, the prognosis for BAL remains poor 
and treatment protocols devised specifically for this entity should 
be investigated in prospective studies.
